Verve Therapeutics (NASDAQ:VERV) Price Target Raised to $24.00 at Guggenheim

Verve Therapeutics (NASDAQ:VERV - Free Report) had its price objective raised by Guggenheim from $18.00 to $24.00 in a research note issued to investors on Tuesday morning, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

Several other analysts have also recently commented on the stock. HC Wainwright raised their target price on shares of Verve Therapeutics from $15.00 to $25.00 and gave the stock a "buy" rating in a research note on Monday, April 14th. Canaccord Genuity Group boosted their target price on Verve Therapeutics from $32.00 to $39.00 and gave the stock a "buy" rating in a research report on Tuesday, April 15th. William Blair restated an "outperform" rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Cantor Fitzgerald upgraded shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Finally, Royal Bank of Canada cut their price target on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verve Therapeutics currently has an average rating of "Buy" and a consensus target price of $25.75.

Verve Therapeutics Stock Up 1.8 %

VERV stock traded up $0.08 during trading on Tuesday, hitting $4.59. The company had a trading volume of 2,590,118 shares, compared to its average volume of 1,710,185. The firm has a 50-day moving average price of $5.63 and a 200-day moving average price of $5.92. The firm has a market cap of $407.57 million, a PE ratio of -1.87 and a beta of 1.86. Verve Therapeutics has a 1-year low of $2.86 and a 1-year high of $9.31.

Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business had revenue of $13.08 million for the quarter, compared to analyst estimates of $3.94 million. Sell-side analysts anticipate that Verve Therapeutics will post -2.49 earnings per share for the current year.

Institutional Trading of Verve Therapeutics

Institutional investors have recently bought and sold shares of the company. BVF Inc. IL raised its stake in shares of Verve Therapeutics by 962.2% during the 4th quarter. BVF Inc. IL now owns 6,904,050 shares of the company's stock worth $38,939,000 after buying an additional 6,254,050 shares during the last quarter. State Street Corp increased its holdings in Verve Therapeutics by 27.0% during the 3rd quarter. State Street Corp now owns 4,253,217 shares of the company's stock valued at $20,586,000 after acquiring an additional 903,809 shares in the last quarter. Schonfeld Strategic Advisors LLC raised its position in Verve Therapeutics by 57.4% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company's stock worth $21,372,000 after acquiring an additional 1,382,176 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Verve Therapeutics by 18.5% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company's stock valued at $10,423,000 after purchasing an additional 288,678 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in shares of Verve Therapeutics by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,625,780 shares of the company's stock valued at $9,172,000 after purchasing an additional 25,093 shares during the last quarter. 97.11% of the stock is currently owned by hedge funds and other institutional investors.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.